RxDoctor Payments Data

Donald Stewart, MD

Urology · Waco, TXNPI 1932212487

Payments from drug & device makers

$1,650in general payments, 2019–2025

Across 33 payments — averaging $49.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$743
  • Boston Scientific$354
  • Astellas Pharma US Inc$234
  • Axonics, Inc.$78
  • Urogen Pharma, Inc.$64
  • Johnson & Johnson$50
  • plus $126 from 6 others

What the payments were for

  • Travel & lodging$282%
  • Food & beverage$1,60697%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,650 in reported general payments places this provider in the 30th percentile of 878 urology providers in Texas.

See all urology providers in Texas

Medicare billing

Part B allowed, 2024
$121,097
Medicare patients
555
Services billed
1,900

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide19$270,333
MyrbetriqMirabegron120$77,109
Tamsulosin Hcl868$14,256
Mirabegron ErMirabegron22$10,696
Finasteride643$9,343
Testosterone Cypionate84$4,172
NitrofurantoinNitrofurantoin Macrocrystal78$3,807
Tolterodine Tartrate67$3,784
Estradiol43$3,215
Bicalutamide74$2,923
Oxybutynin Chloride154$2,519
Potassium Citrate ErPotassium Citrate38$2,407
Alfuzosin Hcl ErAlfuzosin Hcl74$1,737
Ciprofloxacin Hcl228$1,675
Trospium Chloride41$1,407

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$234$347,442139 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 878 urology providers in Texas.

Other urology in Waco

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →